Samsung Bioepis Appeals to Patients Through Package Design


In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.

Can you make a biosimilar package more appealing for a patient? What would you change? Those were the questions that designers at Samsung Bioepis pondered as they sought unifying design elements they could use across their drug portfolio while still enabling patients and doctors to distinguish one product from another.

They appear to have succeeded. The Incheon, Republic of Korea—based company won 2 prestigious Red Dot Design Awards for its soft-yet-engaging product designs that feature basic shapes and soothing colors, such as a purple, fruit-like shape for its infliximab product (Renflexis, Flixabi, Remaloce) and a fusion of green or blue circular shapes for its etanercept biosimilar (Eticovo, Brenzys, Benepali, Etoloce).

Meanwhile, Samsung Bioepis’ trastuzumab contender (Ontruzant, Samfenet) was given a solid, salmon-colored tulip-like shape.

The company called the redesign “Passion for Health: Pure Joy in Life.” It draws from tranquil, organic forms to evoke mental and physical stability in patients who are struggling with their health conditions.

“It was designed with a motive to bring out life and joy for patients with chronic illness,” Samsung Bioepis said. “The focus of the design was ‘process of healing’ by using soft graphics in order to move away from the conventional, rigid design of medicine packaging, which only serves to deliver safety information.”

Samsung Bioepis won the Brand Design & Identity and Packaging Design awards in this year’s Red Dot contest. The company has been part of a wave of biosimilar industry powering up in Republic of Korea, which has enjoyed double-digit growth for the past 5 years.

Related Videos
Fran Gregory, PharmD, MBA
Julie Reed
Julie Reed, executive director of the Biosimilars Forum
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Ryan Haumschild, PharmD, MS, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
andre harvin
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Andre Harvin, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.